Incorporating Emerging Innovation in Hemophilia A and B: Tailoring Prophylaxis and Management Strategies in the Managed Care Environment

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Chris Barton, LCSW, of Horizon Blue Cross Blue Shield of New Jersey, explores how the Youth Behavioral Health Strategy program focuses on addressing the specific needs of youth with mental health and substance use issues through a comprehensive approach.

Immunosuppressants used in adeno-associated virus (AAV) gene therapy for monogenic disorders present an adverse effect profile that is consistent with high-dose steroid use in other conditions, according to a meta-study that analyzed immunosuppressive protocols.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this third episode, we speak with Kim MacDonald-Wilson, ScD, CPRP, and Tracy Carney, CPS, CPRP.

The toxicity of lung cancer treatment has traditionally been discussed in terms of physical symptoms, but there is a growing focus on financial toxicity, time toxicity, and other effects on well-being, as reflected in research presented at the 2024 World Conference on Lung Cancer.

Genetic variability and sex-specific differences may play a role in sickle cell disease (SCD)-related pain; however, more research is needed.